Pfizer and Mylan have formed a long-term collaboration to develop and market generic drugs in Japan. The two companies will continue to operate as independent entities but will collaborate on current and future generic products and will share costs and profits. The collaboration will initially include 350 marketed products and more than 125 additional products in development that will be sold under the Pfizer brand with joint labelling. The Japanese generics market offers attractive growth prospects, not least because of Japanese government plans to increase the generic utilisation rate in the country.